USCOM LIMITED — Capital/Financing Update 2015

Apr 29, 2015

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

USCOM Receives Research and Development Tax Incentive Payment

Sydney, Australia: Thursday, 30[th ] April 2015: Uscom (ASX code: UCM) (the Company or Uscom ), a revenue stage, cardiovascular medical technology company and manufacturer of the USCOM 1A and USCOM BP+, is pleased to confirm the receipt of $313,050 as re-imbursement in respect of eligible research and development (R&D) activities for the 2014 tax year.

The R&D Tax Incentive is targeted to support R&D programs which benefit Australians and is administered jointly by AusIndustry (on behalf of Innovation Australia) and the Australian Taxation Office.

Uscom CEO, Associate Professor Rob Phillips said, “ This is a really important and effective Australian Federal Government policy run to support Australian R&D activities which contribute to the welfare of all Australians. R&D is a vital part of the Uscom business and ensures that our products remain at the cutting edge of global medical technology. The R&D tax incentive program also ensures that the benefits of Australian innovation and entrepreneurship are both directly delivered to Australians, and indirectly through the generation of high value add, highly technical, skilled and clean employment. The program is a well administered and vital part of Government policy supporting Australian innovation, manufacturing and employment .”

On going Uscom R&D programs are focused on development and improvements to the current range of Uscom products and as background for new products.

References:

https://www.ato.gov.au/Business/Research-and-development-tax-incentive/

About Uscom

Uscom Limited (UCM) is an ASX listed cardiovascular medical device company. Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the Uscom BP+. Both devices are clinically validated with FDA, CE and TGA regulatory registration, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects circulatory abnormalities and guides treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, heart failure, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread sub systolic Blood Pressure monitoring technology. Central Blood Pressure is emerging as the new standard of care in hypertension and heart failure. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and arterial pulse pressure waveforms, measures otherwise only available by cardiac catheterisation. The Uscom BP+ is simple to use and measures from a familiar upper arm cuff, and requires no complex training, and has applications in cardiology, intensive care, general practice and home care.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Assoc. Professor Rob Phillips Executive Chairman rob@uscom.com.au

Catherine Officer Company Secretary secretary@uscom.com.au